Showing 9,801 - 9,820 results of 18,406 for search 'significantly ((((((less decrease) OR (nn decrease))) OR (mean decrease))) OR (a decrease))', query time: 0.58s Refine Results
  1. 9801
  2. 9802
  3. 9803
  4. 9804

    Primers for qPCR. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  5. 9805

    Antibodies used for western blotting. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  6. 9806

    Target sequences of siRNAs. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  7. 9807

    Plasmids information. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  8. 9808

    Raw data. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  9. 9809

    Table 1_The association between oxidative balance scores and all-cause mortality and cancer-specific mortality in cancer survivors: a retrospective cohort study.doc by Ran He (207626)

    Published 2025
    “…A similar significant association was found with cancer-specific mortality, while no significant association was noted for CVD mortality. …”
  10. 9810

    Clinical and epidemiological data of patients. by Mailma Costa de Almeida (22057684)

    Published 2025
    “…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”
  11. 9811

    Supplementary Material for: SPECKLE TRACKING ECHOCARDIOGRAPHY IN TWIN PREGNANCIES AND THE ROLE OF GLOBAL LONGITUDINAL STRAIN AND PEAK SYSTOLIC STRAIN: A SYSTEMATIC REVIEW AND META-... by Meireson E. (20224101)

    Published 2024
    “…The global longitudinal strain in the right and left ventricle and the peak systolic strain in the right ventricle of the recipient MCDA twin is significantly decreased compared to the donor MCDA twin. 2D STE assessment was shown feasible and reproducible in MCDA pregnancies. …”
  12. 9812

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  13. 9813

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  14. 9814

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  15. 9815

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  16. 9816

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  17. 9817

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  18. 9818

    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  19. 9819

    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  20. 9820

    WHODAS Outcomes (ITT Analysis). by Mailma Costa de Almeida (22057684)

    Published 2025
    “…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”